Skip to navigation Skip to content

CD30 positive systemic anaplastic large cell lymphoma program in Pharmaceutical Benefits Scheme (PBS) 012-18051139

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised brentuximab vedotin for patients with CD30 positive systemic anaplastic large cell lymphoma (sALCL).

For information on how to process a PBS Authority, see Processing Complex Authority Required Listings. Contact a Local Peer Support (LPS) if unsure on how to action an application

CD30 positive systemic anaplastic large cell lymphoma quick reference

Restrictions

Authority level and section

PA assessment

Processing system

Prescriber type

Prescriber self-serve

Initial

PB123 form

Written

Electronic

S100:
brentuximab vedotin

No

OPA

Not specified

Yes

Continuing

Telephone

Electronic

S100:
brentuximab vedotin

No

OPA

Not specified

Yes